A Study of TAK-411 in Adults With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) (NCT06798012)
A Phase 2, Open-label, Proof-of-Concept Study to Investigate the Efficacy, Safety, and Tolerability of TAK-411 in Adult Subjects With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (The CASCA Study)
🩺 Plain-English Summary (8th-Grade Level)
CIDP is an autoimmune disease. This means that the body's germ fighting (immune) system attacks itself. In CIDP, the immune system attacks the protective covering around the nerves called myelin. Over time, these nerves lose their ability to send signals to the muscles in the body. This leads to muscle weakness and loss of sensation in arms and legs among other symptoms. Participants with CIDP can be treated with a protein called immunoglobulin (or IG). TAK-411 is a special type of immune globulin G (hsIgG) that has been chemically changed. It is made from IG that comes from human plasma. This study will test if TAK-411 can decrease inflammation and improve symptoms of CIDP. The main aim of this study is to check how TAK-411 affects the physical functioning of adults with CIDP when compared with results of the placebo group of a historical trial. Participants may be treated with TAK-411 for up to 1 year (51 weeks) and will be followed up for 3 weeks after last dose. During the study, participants may visit their study clinic up to approximately 21 times.
Who can join: Review the eligibility criteria below.
Location: University of California San Diego — La Jolla, California
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (20 Sites)
- University of California San Diego — La Jolla, California
- California Pacific Medical Center — San Francisco, California
- UF Health Neurology - Jacksonville — Jacksonville, Florida
- Visionary Investigators Network — Miami, Florida
- University of South Florida — Tampa, Florida
- Emory University — Atlanta, Georgia
- Beth Israel Deaconess Medical Center — Boston, Massachusetts
- Mayo Clinic Rochester — Rochester, Minnesota
- The Curators of the University of Missouri on behalf of University of Missouri Health Care — Columbia, Missouri
- The Washington University — St Louis, Missouri
- Penn Blood Disorders Program - Hospital of The University of Pennsylvania — Philadelphia, Pennsylvania
- Houston Methodist Research Institute — Houston, Texas
- University of Washington — Seattle, Washington
- University of Calgary — Calgary, Alberta
- University Health Network — Toronto, Ontario
- Neuro ClinicaS.A.S — Medellín, Antioquia
- Hospital Universitario San Ignacio — Bogotá, D.C.
- Fundacion Valle del Lili — Cali, Valle del Cauca Department
- Universidad del Rosario — Bogotá,
- Fundacion Oftalmologica de Santander - FOSCAL — Bucaramanga,
📞 Contact the Study Coordinator
Phone: (877) 825-3327
Email: medinfoUS@takeda.com
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)
Explore by condition: All Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.